3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
46
Colorectal Neoplasms
33
Stomach Neoplasms
31
Esophageal Squamous Cell Carcinoma
27
Esophageal Neoplasms
14
Rectal Neoplasms
12
Cholangiocarcinoma
11
Colonic Neoplasms
9
Pancreatic Neoplasms
7
Neoplasm Metastasis
6
Sarcoma
5
Carcinoma, Non-Small-Cell Lung
5
Locally Advanced Rectal Cancer
4
Biliary Tract Neoplasms
4
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Melanoma
3
Liver Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma
3
Adenocarcinoma Of Esophagus
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
HER2-positive Gastric Cancer
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Interventions
pembrolizumab
3
Nivolumab
2
tislelizumab
1
Trastuzumab
1
Tablets
1
Specimen Handling
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Magnetic Resonance Spectroscopy
1
Ipilimumab
1
Immunotherapy
1
Imatinib Mesylate
1
Drug Therapy
1
Docetaxel
1
Cyclophosphamide
1
Combined Modality Therapy
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Biological Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Adenoid Cystic
×
tislelizumab
×
Gastrointestinal
×
Clear all
NCT03287427
2023-02-15
MYPHISMO
Peter MacCallum Cancer Centre, Australia
Phase 1
Completed
27 enrolled